BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 – ) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy

Hope S. Rugo; Giulia Valeria Bianchi; Stephen K. L. Chia; Nicholas C. Turner; Dejan Juric; William Jacot; Manuel Ruiz Borrego; Linnea I. Chap; Ursa Abigail Brown-Glaberman; Carolyn C. Nienstedt; Nikos Sophos; Antonia Ridolfi; Chinjune Lin; Eva Ciruelos

doi:10.1200/JCO.2018.36.15_suppl.TPS1107

Retour

BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 – ) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy

Article de revue

Avec comité de lecture

BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 – ) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy

Hope S. Rugo, Giulia Valeria Bianchi, Stephen K. L. Chia, Nicholas C. Turner, Dejan Juric, William Jacot, Manuel Ruiz Borrego, Linnea I. Chap, Ursa Abigail Brown-Glaberman, Carolyn C. Nienstedt, …

Journal of clinical oncology, Vol.36(15_suppl), pp.TPS1107-TPS1107

20/05/2018

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS1107

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

Détails

Titre: BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 – ) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy
Créateurs - sans rôle: Hope S. Rugo - University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Giulia Valeria Bianchi - Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Stephen K. L. Chia - BC Cancer Agency, Vancouver, BC, Canada
Nicholas C. Turner - Royal Marsden NHS Foundation Trust, London, United Kingdom
Dejan Juric - Massachusetts General Hospital Cancer Center, Boston, MA
William Jacot - Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France
Manuel Ruiz Borrego - Hospital Universitario Virgen del Rocío, Seville, Spain
Linnea I. Chap - Beverly Hills Cancer Center, Beverly Hills, CA
Ursa Abigail Brown-Glaberman - UNM Cancer Center, Albuquerque, NM
Carolyn C. Nienstedt - Novartis Pharmaceuticals Corporation, East Hanover, NJ
Nikos Sophos - Novartis Pharmaceuticals Corporation, East Hanover, NJ
Antonia Ridolfi - Novartis Pharmaceuticals S.A.S., Rueil-Malmaison, France
Chinjune Lin - Novartis Pharmaceuticals Corporation, East Hanover, NJ
Eva Ciruelos - Breast Cancer Unit, University Hospital, Madrid, Spain
Détails de publication: Journal of clinical oncology, Vol.36(15_suppl), pp.TPS1107-TPS1107
Identifiants: 99140135109311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article